Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2022 Publisher: Mylan Products Ltd, Station Close, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom
Rhinolast Nasal Spray.
| Pharmaceutical Form |
|---|
|
Nasal spray. |
Azelastine Hydrochloride 0.1% w/v.
| Active Ingredient | Description | |
|---|---|---|
| Azelastine |
Azelastine, a phthalazinone derivative is classified as a potent long-acting anti-allergic compound with selective H1 antagonist properties. An additional anti-inflammatory effect could be detected after topical ocular administration. Data from in vivo (pre-clinical) and in vitro studies show that azelastine inhibits the synthesis or release of the chemical mediators known to be involved in early and late stage allergic reactions e.g. leukotriene, histamine, PAF and serotonin. |
| List of Excipients |
|---|
|
Hypromellose |
Polyethylene bottle with polypropylene cap and polyethylene seal containing either 10 ml or 20 ml.
Glass bottle with screw closure and polypropylene seal containing 10 ml, 20 ml or 22 ml.
Glass bottle with pump attached containing 10 ml, 20 ml or 22 ml.
10 ml glass bottle with pump attached, containing 5 ml aqueous solution.
10 ml polyethylene bottle with polypropylene cap and polyethylene seal, containing 5 ml aqueous solution.
Mylan Products Ltd, Station Close, Potters Bar, Hertfordshire, EN6 1TL, United Kingdom
PL 46302/0140
14th August 2009
| Drug | Countries | |
|---|---|---|
| RHINOLAST | Ireland, Israel, Malta, New Zealand, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
